GlaxoSmithKline (NYSE: GSK) is on watch Thursday following news its Paxil antidepressant was found to be unsafe and ineffective for teenagers.

The NY Times noted a report in the journal BMJ on the info.

According to the BMJ article: A major reanalysis just published in The BMJ of tens of thousands of pages of original trial documents from GlaxoSmithKline’s infamous Study 329, has concluded that the antidepressant paroxetine is neither safe nor effective in adolescents with depression.1 This conclusion, drawn by independent researchers, is in direct contrast to that of the trial’s original journal publication in 2001, which had proclaimed paroxetine “generally well tolerated and effective.” The new paper, published under the restoring invisible and abandoned trials (RIAT) initiative, has reignited calls for retraction of the original study, putting additional pressure on academic and professional institutions to publicly address the many allegations of wrongdoing.

Again, the BMJ article can be accessed here.